未接受抗逆转录病毒治疗的HIV控制者非艾滋病定义事件风险低于接受抑制性抗逆转录病毒治疗的正常进展者
本研究比较未接受抗逆转录病毒治疗(ART)的HIV控制者与接受抑制性ART的正常进展者(NP-ART)的非艾滋病定义事件(nADE)风险,并评估HIV控制者启动ART后的nADE风险。纳入1007例未治疗HIV控制者、1510例早期ART者和15437例NP-ART参照组。HIV控制者主要终点、全因死亡和心血管疾病风险低于NP-ART,但非艾滋病恶性肿瘤风险无显著差异;HIV控制者中ART未降低nADE风险。
要点
- 与NP-ART相比,HIV控制者主要终点风险更低(HR 0.55,95%CI 0.38-0.81,P=0.0023)。
- HIV控制者全因死亡和心血管疾病风险低于NP-ART,非艾滋病恶性肿瘤无显著差异。
- HIV控制者中启动ART未降低任何nADE风险(aHR 1.22,95%CI 0.66-2.29,P=0.53)。
核心结论
- HIV控制者的nADE风险低于NP-ART,尤其在血浆病毒载量低者中;ART未改变HIV控制者的nADE风险。
研究设计与样本
- 比较未接受ART的HIV控制者、早期ART者(HIV检测阴性后<6个月)与NP-ART参照组的nADE风险,ART在HIV控制者中作为时变协变量评估。
- 纳入1007例未治疗HIV控制者(其中60例为精英控制者)、1510例早期ART者和15437例NP-ART参照组,随访人年分别为3813、11060和160050。
主要发现
- 与NP-ART相比,HIV控制者主要终点风险更低(HR 0.55,95%CI 0.38-0.81,P=0.0023)。
- 与NP-ART相比,HIV控制者全因死亡风险更低(aHR 0.45,95%CI 0.25-0.79,P=0.0054)。
- 与NP-ART相比,HIV控制者心血管疾病风险更低(aHR 0.47,95%CI 0.22-0.99,P=0.046)。
- 与NP-ART相比,HIV控制者非艾滋病恶性肿瘤风险无显著差异(aHR 0.74,95%CI 0.41-1.35,P=0.33)。
- HIV控制者中基线病毒载量每降低1 log10,nADE风险进一步降低(aHR 0.54,95%CI 0.29-0.99,P=0.045)。
临床怎么用
- 作者认为,该发现有助于临床医生决定是否给HIV控制者处方ART。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to compare the non-AIDS event (nADE) risk between normal progressors using antiretroviral therapy (NP-ART) and people with human immunodeficiency virus (HIV, PWH) who naturally control HIV infection (HIV controllers), as well as the risk of nADE following ART in HIV controllers. METHODS: The primary end point was the composite of cardiovascular disease, non-AIDS malignancy, or all-cause mortality, whichever came first. The role of ART in HIV controllers was assessed as a time-varying covariate. RESULTS: We included 1007 ART-naive HIV controllers (60 of them were elite controllers), 1510 early-ART (<6 months after negative HIV test), and 15437 NP-ART (reference group), contributing 3813, 11 060, and 160 050 years of follow-up, respectively. HIV controllers had lower risk of the primary end point (hazard ratio [HR], 0.55; 95% confidence interval [CI]: .38-.81; P = .0023), all-cause mortality (adjusted HR [aHR], 0.45; 95% CI: .25-.79; P = .0054), and cardiovascular disease (aHR, 0.47; 95% CI: .22-.99; P = .046), but not non-AIDS malignancy (aHR, 0.74; 95% CI: .41-1.35; P = .33), compared with NP-ART. Among HIV controllers, each log10 lower baseline viral load further decreased the risk of a nADE (aHR, 0.54; 95% CI: .29-.99; P = .045). ART in HIV controllers did not reduce the risk of any nADE (aHR, 1.22; 95% CI: .66-2.29; P = .53). CONCLUSIONS: HIV controllers had a lower n ADE risk than NP-ART, especially in those with low plasma viral loads. ART did not alter the nADE risk in HIV controllers. Our findings help clinicians to decide on prescribing ART in HIV controllers.
引用
- Groenendijk AL, Miranda Afonso P, Wit FWNM, et al. Risk of Non-AIDS-Defining Events Is Lower in Antiretroviral Therapy (ART)-Naive HIV Controllers Than in Normal Progressors on Suppressive ART. Clin Infect Dis. 2025. PMID: 39208446. doi:10.1093/cid/ciae440
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。